June 2008- Volume 4, Issue 6
June 2008
In this Issue
Automation & Instrumentation
Invitrogen intros cell therapy biz unit
Invitrogen intros cell therapy biz unit
Invitrogen Corp., which has been steadily building its cell therapy expertise, announced in mid-May the formation of a separate cell therapy business unit focused on the specific needs of the clinical cell therapy market.
Promega and GeneCopoeia play tag
Promega and GeneCopoeia play tag
Companies combine HaloTag with human and mouse ORF sequences
Geared up for GPCRs
Geared up for GPCRs
DiscoveRx, Caliper team up on microfluidic, cell-based assay deal targeting GPCR researchers
Putting their ChIPs on the table
Putting their ChIPs on the table
Illumina, Genpathway team up to offer whole-genome ChIP sequencing services
Genomics & Proteomics
Yerkes’ monkey business
Yerkes’ monkey business
Researchers develop first transgenic nonhuman primate model of Huntington’s disease
Oligo-ing above and beyond
Oligo-ing above and beyond
Agilent and Broad team up on genome-partitioning kits
Lipid mania
Lipid mania
Lipidoids offer novel RNAi therapy delivery
Hope springs eternal for Benitec’s IP
Hope springs eternal for Benitec’s IP
City of Hope trial helps Benitec to rebuild its RNAi strength
Cancer cohorts
Cancer cohorts
Researchers around the world launch the International Cancer Genome Consortium
Research & Development
On their own again
On their own again
Pfizer sells cholesterol therapy-focused Esperion Therapeutics
A midnight discovery
A midnight discovery
Minerva stumbles upon cancer therapy breakthrough
Profit for non-profit
Profit for non-profit
SFBR launches for-profit drug company focused on women’s health concerns
UF compound lowers blood pressure
UF compound lowers blood pressure
University of Florida researchers have identified a drug compound that may prevent tissue damage associated with cardiovascular disease, according to a study published in the May 1 edition of the American Heart Association journal Hypertension.
A one-two diabetes punch
A one-two diabetes punch
DiaKine and Kinexum to develop novel combo treatment for type 1 diabetes
Global News
BMS to buy Kosan for $190M
BMS to buy Kosan for $190M
BMS enhances cancer portfolio in two important anti-cancer classes
Takeda strikes deal with Alnylam
Takeda strikes deal with Alnylam
Non-exclusive platform deal could eventually net Alnylam $1 billion
Protecting your genome
Protecting your genome
Congress passes and president signs genetic antidiscrimination bill
Informatics
The fat cell syndicate
The fat cell syndicate
Entelos lends PhysioLab model to Pfizer diabetes consortium
One-stop data shop
One-stop data shop
LabVantage, InforSense integrate data management and analytics platforms
From bedside to bench
From bedside to bench
GenoLogics develops translational research software for Fred Hutchinson Center
Best of both worlds
Best of both worlds
ClinPhone and invivodata align ePRO solutions
Parkinson’s research 2.0
Parkinson’s research 2.0
The Parkinson’s Institute, 23andMe launch Web-based research initiative
Editor's Focus
Strange bedfellows: Bill Gates and Chairman Mao
Strange bedfellows: Bill Gates and Chairman Mao
News recently out of a discussion at the The Royal Society, London, is raising hopes that an effective and affordable cure for malaria is now on the horizon. But what do both Bill Gates and Chairman Mao have to do with this story? Well, plenty, if you follow the thread and history of malaria treatments.
Patent News
Is it difficult to do deals with universities?
Is it difficult to do deals with universities?
Like many things in life, it’s always easy to criticize the other side. So, what is true?
Commentary
Today’s biopharma venture capital challenge: Risk-sharing models versus risk avoidance
Today’s biopharma venture capital challenge: Risk-sharing models versus risk avoidance
In times like these, when the pendulum of fear swings to risk avoidance, biopharma can only develop products that meet both customer needs and Wall Street expectations through innovative, novel product development based on a reconsidered approach to risk management.
Feature
Trials and tribulations
Trials and tribulations
Effective recruiting for clinical trials requires a commitment to educating patients and physicians
